Sintx Technologies, Inc. (SINT) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Sintx Technologies, Inc.'s filing signal continuing negative.

SINTX Technologies is an advanced ceramics company specializing in the development, manufacturing, and commercialization of silicon nitride biomaterials, composites, and related technologies for medical and industrial applications. The company's core focus is on biomedical solutions, leveraging silicon nitride's biocompatibility, antipathogenic properties, and bone affinity for applications such as spinal implants, arthroplasty, and foot and ankle surgery, having received FDA 510(k) clearance for its SiNAPTIC(R) Foot & Ankle Osteotomy Wedge System in October 2025. SINTX also manufactures silicon nitride parts for electrical, aerospace, and industrial sectors, and is exploring antipathogenic applications for its materials in products like masks and filters, particularly after discovering its silicon nitride inactivates SARS-CoV-2. The company operates its own FDA-registered, ISO 13485 certified manufacturing facility in Salt Lake City, Utah, controlling its entire production process from powder processing to machining and sintering.

Revenue is primarily derived from the sale of products, including aerospace components and spinal fusion products, as well as grant and contract revenue from governmental agencies. The company is also developing proprietary biomedical devices, such as its SiNAPTIC(R) Foot & Ankle Osteotomy Wedge System, and a biologic product, OsseoSculptTM, which are expected to become key revenue drivers.